Chemically Modified Antisense Oligonucleotides for Rpl13a snoRNA Silencing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for atherosclerosis primarily focus on lowering LDL cholesterol levels but fail to address the underlying inflammatory mechanisms, and existing therapies targeting cholesterol-associated inflammation are limited in efficacy and accessibility.

Innovation Solution

Development of antisense oligonucleotides that target and inhibit specific snoRNAs, particularly Rpl13a snoRNAs, to reduce inflammation and mitigate atherosclerosis, using chemically modified sequences to enhance stability and binding affinity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If statin therapy is used to lower LDL cholesterol levels, then the risk of atherosclerosis events is reduced by approximately 30%, but the therapy is unable to reduce LDL-C to ever-tighter goal levels in many patients

Engineering Contradiction:

ImproveLDL cholesterol levelsVSAvoidefficacy to achieve goal levels

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent uses antisense oligonucleotides as intermediary molecules that bind to specific snoRNAs (U32a, U33, U34, U35a) to modulate their function. These oligonucleotides serve as mediators between the therapeutic goal and the biological target, providing a new mechanism to reduce LDL-C levels and address inflammation that statins cannot adequately control.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the therapeutic parameter from单纯 LDL-C lowering to dual action of LDL-C reduction and inflammation suppression. The antisense oligonucleotides target multiple parameters simultaneously: they reduce snoRNA levels, decrease inflammatory markers (IL-1β, CRP), and lower LDL-C, thereby achieving tighter goal levels through multiple mechanisms.

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If current anti-atherosclerosis drugs are used, then LDL cholesterol levels are lowered, but underlying inflammatory mechanisms are not addressed

Engineering Contradiction:

ImproveLDL cholesterol levelsVSAvoidinflammatory mechanisms

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The antisense oligonucleotides exhibit multi-functionality by simultaneously addressing multiple pathological mechanisms: they lower LDL-C levels, suppress inflammation through snoRNA modulation, and reduce atherosclerotic lesion formation. This universal approach treats both the lipid component and inflammatory component of atherosclerosis with a single therapeutic modality.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent extracts and targets specific snoRNAs (U32a, U33, U34, U35a) that are implicated in inflammatory pathways. By using antisense oligonucleotides to specifically bind and silence these snoRNAs, the therapy removes the harmful inflammatory effect mediated by these RNA molecules while preserving other essential cellular functions.

Inventive Principle:

Principle #2Taking out (Extraction)

3Object-affected harmful factors

If existing therapies targeting cholesterol-associated inflammation are used, then some anti-inflammatory effect is achieved, but they are limited in efficacy and accessibility

Engineering Contradiction:

ImproveinflammationVSAvoidefficacy

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent replaces conventional small-molecule anti-inflammatory drugs with a nucleic acid-based therapy (antisense oligonucleotides). This substitution allows for highly specific targeting of snoRNA molecules through complementary base pairing, providing more precise and effective inflammation control compared to broad-spectrum anti-inflammatory agents.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

Instead of using small molecules to inhibit inflammatory enzymes or pathways, the invention uses oligonucleotides to silence the upstream regulatory snoRNAs that control inflammatory gene expression. This inverted approach targets the root cause of inflammation rather than downstream effects, achieving greater efficacy.

Inventive Principle:

Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antisense oligonucleotides effectively decrease inflammation and atherosclerotic lesions, offering a broader anti-inflammatory effect beyond LDL cholesterol reduction, and can be used to treat a range of inflammatory diseases.

Implementation Method 1

an antisense oligonucleotide capable of binding an Rpl13a snoRNA

Methodology Applied

Scientific EffectHybridization:

Implementation Method 2

the oligonucleotide is modified to comprise a phosphorothioate backbone

Methodology Applied

Scientific EffectChemical modification:

Implementation Method 3

the first five 5′ and last five 3′ nucleotides comprise 2′-O-methoxy-ethyl bases (2′-MOE) bases

Methodology Applied

Scientific EffectChemical modification:

Data Source

PatentUS20250290066A1COMPOSITIONS FOR THE SILENCING OF snoRNAS AND METHODS OF USING SAME

Publication Date: 2025.09.18 DUKE UNIV

AI summary

The present disclosure describes, in part, compositions and methods for preventing and treating cardiovascular disease, atherosclerosis and inflammation by inhibiting or decreasing production, expression or activity of Rpl13 snoRNA.